Haemoccult screening for colorectal tumours was carried out in Hungary in small cities and villages around Budapest. Haemoccult slides were supplied to 17 662 individuals over 40 years of age, and 15431 (87%) were returned. Of these, 346 (2.2%) were positive and 18 colorectal carcinomas were detected. Additionally, 24 patients with one or more polyps > 1 cm diameter were found. Of the screened cases of cancer 39% were in Dukes' stage A and B, a rate twice as good as when screening was not done. The cost per tumour detected amounted to about three times more than one monthly income, indicating that the costs of screening for colorectal cancer are relatively much higher in Hungary than in Western countries. All expenses were met from state funds.
Introduction
Colorectal carcinoma is the principal cause of death from malignancy among women in Hungary, having superseded cancer of the breast in 1984. In men it occupies second place after lung cancer. Mortality has increased four-fold during the last 15 years. It is well known that the 5-year survival ofpatients with symptoms of an underlying tumour is less than 40%. For asymptomatic individuals with lesions localized to the mucosa the 5-year survival exceeds 85-90%. The best current hope of improving survival is to find a convenient method to prevent (polypectomy) or detect the cancer at an early stage.
Several large prospective studies in the USA have shown that Haemoccult screening (testing for faecal occult blood) of asymptomatic subjects over the age of 45 years detects 2-3% with malignant or benign tumours' 4. European studies have shown similar results5-13. Faecal occult blood testing by Haemoccult identifies more than three times the annual incidence of colorectal cancer14. Several authors have compared the Haemoccult test with other tests for faecal occult blood15 -8, and found Haemoccult to be both the most effective and simplest method. Farrands et al. 9 had no false-negative results, the specificity for malignancy being 84% (21 falsepositive cases). The level of positivity reached by different authors ranges from 1% to 5%. Among the positive cases about 10% cancers and 30% benign tumours can be found20. These international data are very important in determining the cost-benefit relationship.
The aim of the present study was to compare our methods and results with the international data, in particular the differences in organization, possibilities and costs, and to pinpoint any special national problems.
Patients and methods
The organization and characteristics of the Hungarian health care system are summarized in Table 1 and Figure 1 . The screening programme was undertaken during 1983 in the smaller cities and villages around Budapest following publicity about its aims and measures provided by representatives of the Red Cross, local newspapers and handbills. Haemoccult kits were supplied free of charge to 17 662 individuals aged over 40 by the district doctor or nurse, either at home or during a consultation.
Tests were performed by the district doctor. Positive cases were referred as outpatients to hospital forrigid sigmoidoscopy. Individuals requiringfurther investigation (double contrast enema, colonoscopy) were hospitalized for an average offour days. In calculating costs, only direct expenses were considered (test kits, publicity and organization time, further investigations), the indirect expenses (e.g. time lost from work) being excluded. Dukes' stage C. In 24 patients one or more adenomas were detected and removed, all >1 cm diameter. In addition, 2 gastric and 2 prostate cancers were found.
The total costs of screening and further investigations amounted to 801800 Hungarian forints (Ft), that is 19 090 Ft per tumour detected.
Discussion
Public compliance in completing and returning kits was high (87%) but the number of positives undergoing full gastroenterological investigation was low, particularly after sigmoidoscopy. The rate of detection ofcolorectal cancer -1.2 per 1000 screenedwas much lower than that reported by Hardcastle et Considering this was the first screening programme in a mainly agricultural population, the results are acceptable.
Economic circumstances in Hungary differ substantially from Western countries, but some comparison can be made if costs are considered in relation to a worker's monthly income, which in Hungary in 1983 averaged 6000 Ft. Thus the cost per tumour detected (19 090 Ft) was more than three times one monthly income. In Germany (2022 DM)2" and the USA ($1100)22 the cost ofdetection probably does not exceed one monthly income.
Undeniably the detection and removal ofadenomas is good cancer prophylaxis and saves money. Screening, to be efficient, requires keen district doctors, population compliance and rigorous undeterred follow up. The existing network for screening pulmonary diseases could well be developed into common screening centres.
